Open AccessUpdate on hepatitis C: Direct-acting antivirals
Author(s) -
Leon Louis Seifert,
Ryan B. Perumpail,
Aijaz Ahmed
Publication year - 2015
Publication title -
world journal of hepatology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v7.i28.2829
Subject(s) - medicine , hepatitis c virus , hepatitis c , simeprevir , virology , sofosbuvir , ribavirin , intensive care medicine , virus
Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus. These drugs have revolutionized the management of HCV as all-oral regimens with favorable side effect profiles and superior rates of sustained virological response. Emerging real-world data are demonstrating results comparable to registration trials for DAA agents. Suddenly, the potential for eradicating HCV is on the horizon.